Management ChangeJun 2, 2026, 08:31 AM
Achieve Life Sciences Appoints Jeffrey Farrow & Reid Waldman to Board
AI Summary
Achieve Life Sciences, Inc. announced the appointment of Jeffrey Farrow and Reid Waldman, MD to its Board of Directors. These strategic additions bring significant experience in commercial launches, capital markets, and company building, as Achieve prepares for the NDA resubmission and commercial launch of cytisinicline, a treatment for nicotine dependence. The company aims to introduce the first new prescription smoking cessation medicine in nearly two decades, with cytisinicline also holding Breakthrough Therapy designation for vaping cessation.
Key Highlights
- Jeffrey Farrow and Reid Waldman, MD appointed to Achieve Life Sciences' Board of Directors.
- Jeffrey Farrow is CFO & CSO of Tarsus Pharmaceuticals, with experience in three commercial launches and over $9 billion in acquisitions.
- Reid Waldman, MD is Founder & CEO of Veradermics, which raised $294.8 million in an IPO and $472 million in a follow-on offering in 2026.
- Appointments are strategic as Achieve prepares for cytisinicline's NDA resubmission and commercial launch.
- Cytisinicline aims to be the first new prescription smoking cessation medicine in nearly two decades.
- Cytisinicline has Breakthrough Therapy designation for vaping cessation.
Price Impact
More from ACHV